{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:02:55Z","timestamp":1772064175654,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2B4005720"],"award-info":[{"award-number":["NRF-2017R1A2B4005720"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2B3002241"],"award-info":[{"award-number":["NRF-2017R1A2B3002241"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9E2022820"],"award-info":[{"award-number":["NRF-2018M3A9E2022820"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1A2C2084535"],"award-info":[{"award-number":["NRF-2019R1A2C2084535"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute kidney injury (AKI) is a severe complication of coronavirus disease (COVID-19) that negatively affects its outcome. Concern had been raised about the potential effect of renin\u2013angiotensin\u2013aldosterone system (RAAS) blockades on renal outcomes in COVID-19 patients. However, the association between RAAS blockade use and incident AKI in COVID-19 patients has not been fully understood. We investigated the association between RAAS blockade exposure and COVID-19-related AKI in hospitalized patients through meta-analysis. Electronic databases were searched up to 24th December 2020. Summary estimates of pooled odds ratio (OR) of COVID-19-related AKI depending on RAAS blockade exposure were obtained through random-effects model. The random-effect meta-analysis on fourteen studies (17,876 patients) showed that RAAS blockade use was significantly associated with increased risk of incident AKI in hospitalized COVID-19 patients (OR 1.68; 95% confidence interval 1.19\u20132.36). Additional analysis showed that the association of RAAS blockade use on COVID-19-related AKI remains significant even after stratification by drug class and AKI severity. RAAS blockade use is significantly associated with the incident AKI in hospitalized COVID-19 patients. Therefore, careful monitoring of renal complications is recommended for COVID-19 patients with recent RAAS blockade use due to the potential risk of AKI.<\/jats:p>","DOI":"10.1038\/s41598-021-92323-8","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T10:03:04Z","timestamp":1625047384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Increased risk of acute kidney injury in coronavirus disease patients with renin\u2013angiotensin\u2013aldosterone-system blockade use: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"11","author":[{"given":"Sul A","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Kyung","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Tak","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hyeok","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"92323_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"92323_CR2","unstructured":"Horby, P. et al. Dexamethasone in hospitalized patients with covid-19: Preliminary report. N Engl J Med (2020)."},{"key":"92323_CR3","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of covid-19: Final report. N. Engl. J. Med. 383, 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92323_CR4","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"P Horby","year":"2020","unstructured":"Horby, P. et al. Effect of hydroxychloroquine in hospitalized patients with covid-19. N. Engl. J. Med. 383, 2030\u20132040 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92323_CR5","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA 324, 460\u2013470 (2020).","journal-title":"JAMA"},{"key":"92323_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/0886022X.2020.1756323","volume":"42","author":"H Ali","year":"2020","unstructured":"Ali, H. et al. Survival rate in acute kidney injury superimposed COVID-19 patients: A systematic review and meta-analysis. Ren. Fail. 42, 393\u2013397 (2020).","journal-title":"Ren. Fail."},{"key":"92323_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41581-020-00356-5","volume":"16","author":"MK Nadim","year":"2020","unstructured":"Nadim, M. K. et al. COVID-19-associated acute kidney injury: Consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat. Rev. Nephrol. 16, 747\u2013764 (2020).","journal-title":"Nat. Rev. Nephrol."},{"key":"92323_CR8","doi-asserted-by":"publisher","first-page":"e042573","DOI":"10.1136\/bmjopen-2020-042573","volume":"10","author":"L Lin","year":"2020","unstructured":"Lin, L. et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: A meta-analysis. BMJ Open 10, e042573 (2020).","journal-title":"BMJ Open"},{"key":"92323_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1159\/000511160","volume":"51","author":"U Zahid","year":"2020","unstructured":"Zahid, U. et al. Acute kidney injury in COVID-19 patients: an inner city hospital experience and policy implications. Am. J. Nephrol. 51, 786\u2013796 (2020).","journal-title":"Am. J. Nephrol."},{"key":"92323_CR10","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang, L., Karakiulakis, G. & Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir. Med. 8, e21 (2020).","journal-title":"Lancet Respir. Med."},{"key":"92323_CR11","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1111\/bph.15082","volume":"177","author":"K Sriram","year":"2020","unstructured":"Sriram, K. & Insel, P. A. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1\/ACE2 imbalance. Br. J. Pharmacol. 177, 4825\u20134844 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"92323_CR12","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin-angiotensin-aldosterone system blockers and the risk of covid-19. N. Engl. J. Med. 382, 2431\u20132440 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92323_CR13","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"382","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin-angiotensin-aldosterone system inhibitors and risk of covid-19. N. Engl. J. Med. 382, 2441\u20132448 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92323_CR14","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","volume":"395","author":"FJ de Abajo","year":"2020","unstructured":"de Abajo, F. J. et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: A case-population study. Lancet 395, 1705\u20131714 (2020).","journal-title":"Lancet"},{"key":"92323_CR15","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II Receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ. Res. 126, 1671\u20131681 (2020).","journal-title":"Circ. Res."},{"key":"92323_CR16","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.accpm.2020.06.006","volume":"39","author":"E Dudoignon","year":"2020","unstructured":"Dudoignon, E. et al. Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19. Anaesth Crit. Care Pain Med. 39, 453\u2013455 (2020).","journal-title":"Anaesth Crit. Care Pain Med."},{"key":"92323_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa677","author":"A Oussalah","year":"2020","unstructured":"Oussalah, A. et al. Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: Results from a referral center cohort in the North East of France. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa677 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"92323_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/ajh\/hpaa149","volume":"33","author":"A Soleimani","year":"2020","unstructured":"Soleimani, A. et al. Effects of angiotensin receptor blockers (ARBs) on in-hospital outcomes of patients with hypertension and confirmed or clinically suspected COVID-19. Am. J. Hypertens. 33, 1102\u20131111 (2020).","journal-title":"Am. J. Hypertens."},{"key":"92323_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.2162","volume":"212","author":"I Hamming","year":"2007","unstructured":"Hamming, I. et al. The emerging role of ACE2 in physiology and disease. J. Pathol. 212, 1\u201311 (2007).","journal-title":"J. Pathol."},{"key":"92323_CR20","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1021\/acschemneuro.0c00210","volume":"11","author":"K Bilinska","year":"2020","unstructured":"Bilinska, K., Jakubowska, P., Von Bartheld, C. S. & Butowt, R. Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: Identification of cell types and trends with age. ACS Chem. Neurosci. 11, 1555\u20131562 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"92323_CR21","doi-asserted-by":"publisher","first-page":"H1084","DOI":"10.1152\/ajpheart.00217.2020","volume":"318","author":"AM South","year":"2020","unstructured":"South, A. M., Diz, D. I. & Chappell, M. C. COVID-19, ACE2, and the cardiovascular consequences. Am. J. Physiol. Heart Circ. Physiol. 318, H1084-h1090 (2020).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"92323_CR22","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586\u2013590 (2020).","journal-title":"Intensive Care Med."},{"key":"92323_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","volume":"382","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Renin-angiotensin-aldosterone system inhibitors in patients with covid-19. N. Engl. J. Med. 382, 1653\u20131659 (2020).","journal-title":"N. Engl. J. Med."},{"key":"92323_CR24","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1111\/bcp.14660","volume":"87","author":"C Chu","year":"2020","unstructured":"Chu, C. et al. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis. Br. J. Clin. Pharmacol. 87, 2475 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"92323_CR25","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/jmv.26625","volume":"93","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 93, 1370 (2020).","journal-title":"J. Med. Virol."},{"key":"92323_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-020-00880-6","volume":"22","author":"R Baral","year":"2020","unstructured":"Baral, R., White, M. & Vassiliou, V. S. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: A systematic review and meta-analysis of 28,872 patients. Curr. Atheroscle. Rep. 22, 61 (2020).","journal-title":"Curr. Atheroscle. Rep."},{"key":"92323_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000505896","volume":"51","author":"SG Coca","year":"2020","unstructured":"Coca, S. G. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers after acute kidney injury: Friend, foe, or acquaintance?. Am. J. Nephrol. 51, 263\u2013265 (2020).","journal-title":"Am. J. Nephrol."},{"key":"92323_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes, R. D. et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A Randomized Clinical Trial. JAMA 325, 254\u2013264 (2021).","journal-title":"JAMA"},{"key":"92323_CR29","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","volume":"178","author":"S Brar","year":"2018","unstructured":"Brar, S. et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern. Med. 178, 1681\u20131690 (2018).","journal-title":"JAMA Intern. Med."},{"key":"92323_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-020-01659-x","volume":"18","author":"P Bidulka","year":"2020","unstructured":"Bidulka, P. et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: Parallel population-based cohort studies in English and Swedish routine care. BMC Med. 18, 195 (2020).","journal-title":"BMC Med."},{"key":"92323_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1159\/000505893","volume":"51","author":"A Hines","year":"2020","unstructured":"Hines, A. et al. Use of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and acute kidney disease after an episode of AKI: A multicenter prospective cohort study. Am. J. Nephrol. 51, 266\u2013275 (2020).","journal-title":"Am. J. Nephrol."},{"key":"92323_CR32","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1016\/j.jacc.2020.04.028","volume":"75","author":"A Brojakowska","year":"2020","unstructured":"Brojakowska, A., Narula, J., Shimony, R. & Bander, J. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC Review topic of the week. J. Am. Coll. Cardiol. 75, 3085\u20133095 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"92323_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/ehjcvp\/pvaa021","volume":"6","author":"G de Simone","year":"2020","unstructured":"de Simone, G. & Mancusi, C. Speculation is not evidence: Antihypertensive therapy and COVID-19. Eur. Heart J. Cardiovasc. Pharmacother. 6, 133\u2013134 (2020).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"92323_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.14423\/SMJ.0000000000001200","volume":"114","author":"AAD Albashir","year":"2021","unstructured":"Albashir, A. A. D. Renin-angiotensin-aldosterone system (RAAS) inhibitors and coronavirus disease 2019 (COVID-19). South Med. J. 114, 51\u201356 (2021).","journal-title":"South Med. J."},{"key":"92323_CR35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.34067\/KID.0003792020","volume":"1","author":"I Chaudhri","year":"2020","unstructured":"Chaudhri, I. et al. Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection. Kidney 1, 801 (2020).","journal-title":"Kidney"},{"key":"92323_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.34067\/KID.0000562019","volume":"1","author":"Y Cheng","year":"2020","unstructured":"Cheng, Y. et al. Risk factors and outcomes of acute kidney injury in critically ill patients with coronavirus disease 2019. Kidney Dis. 1, 1\u20139 (2020).","journal-title":"Kidney Dis."},{"key":"92323_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.kint.2020.05.006","volume":"98","author":"JS Hirsch","year":"2020","unstructured":"Hirsch, J. S. et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 98, 209\u2013218 (2020).","journal-title":"Kidney Int."},{"key":"92323_CR38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/ndt\/gfaa162","volume":"35","author":"F Husain-Syed","year":"2020","unstructured":"Husain-Syed, F. et al. Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019. Nephrol. Dial. Transplant. 35, 1271\u20131274 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"92323_CR39","doi-asserted-by":"publisher","first-page":"e1003406","DOI":"10.1371\/journal.pmed.1003406","volume":"17","author":"NV Kolhe","year":"2020","unstructured":"Kolhe, N. V., Fluck, R. J., Selby, N. M. & Taal, M. W. Acute kidney injury associated with COVID-19: A retrospective cohort study. PLoS Med. 17, e1003406 (2020).","journal-title":"PLoS Med."},{"key":"92323_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1159\/000439146","volume":"131","author":"NM Selby","year":"2015","unstructured":"Selby, N. M., Hill, R. & Fluck, R. J. Standardizing the early identification of acute kidney injury: The NHS England National Patient Safety Alert. Nephron 131, 113\u2013117 (2015).","journal-title":"Nephron"},{"key":"92323_CR41","doi-asserted-by":"publisher","first-page":"20250","DOI":"10.1038\/s41598-020-76915-4","volume":"10","author":"JH Lim","year":"2020","unstructured":"Lim, J. H. et al. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: A retrospective cohort study. Sci. Rep. 10, 20250 (2020).","journal-title":"Sci. Rep."},{"key":"92323_CR42","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.accpm.2020.100788","volume":"40","author":"G Louis","year":"2020","unstructured":"Louis, G., Belveyre, T., Goetz, C., Gaci, R. & Dinot, V. Acute kidney injury in severe SARS-CoV-2 infection: An experience report in Eastern France. Anaesth. Crit. Care Pain. Med. 40, 100788 (2020).","journal-title":"Anaesth. Crit. Care Pain. Med."},{"key":"92323_CR43","unstructured":"Ng, J. H. et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis (2020)."},{"key":"92323_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000509182","volume":"10","author":"J Pelayo","year":"2020","unstructured":"Pelayo, J. et al. Clinical characteristics and outcomes of community- and hospital-acquired acute kidney injury with COVID-19 in a US Inner City Hospital System. Cardiorenal. Med. 10, 223\u2013231 (2020).","journal-title":"Cardiorenal. Med."},{"key":"92323_CR45","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1093\/ndt\/gfaa288","volume":"35","author":"S Peng","year":"2020","unstructured":"Peng, S. et al. Early versus late acute kidney injury among patients with COVID-19-a multicenter study from Wuhan, China. Nephrol. Dial. Transplant. 35, 2095\u20132102 (2020).","journal-title":"Nephrol. Dial. Transplant."},{"key":"92323_CR46","first-page":"1","volume":"1","author":"E Russo","year":"2020","unstructured":"Russo, E. et al. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. J. Nephrol. 1, 1\u201311 (2020).","journal-title":"J. Nephrol."},{"key":"92323_CR47","first-page":"e9693","volume":"12","author":"A Taher","year":"2020","unstructured":"Taher, A., Alalwan, A. A., Naser, N., Alsegai, O. & Alaradi, A. Acute kidney injury in covid-19 pneumonia: A single-center experience in Bahrain. Cureus 12, e9693 (2020).","journal-title":"Cureus"},{"key":"92323_CR48","first-page":"2","volume":"1","author":"S Tetlow","year":"2020","unstructured":"Tetlow, S. et al. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J. Intern. Med. 1, 2\u201320 (2020).","journal-title":"J. Intern. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92323-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92323-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T11:13:05Z","timestamp":1675509185000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-92323-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["92323"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-92323-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tae-Hyun Yoo is a Scientific Advisory Board member at ILIAS Biologics Inc. All authors have no additional conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13588"}}